NovaDigm Therapeutics
Grand Forks
About NovaDigm Therapeutics
NovaDigm Therapeutics develops vaccines to protect patients from fungal and bacterial infections. Its products include NDV-3, a vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by fungal and bacterial pathogens; and Als3, an antigen vaccine, which provides protection against systemic and mucosal candidal infections. It was founded in 2005 and headquartered in Grand Forks, North Dakota.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $57.8M
- Funding stage: Early Stage Venture
- Last round: Grant (Jun 2017)
- Website: novadigm.net
- Phone: 7013357121
Industries & Categories
Biotechnology, Health Care, Medical Device, Therapeutics
Canonical: https://fsome.com/organization/novadigm-therapeutics-5075 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.